Somatic Hypermutation

Somatic hypermutation (SHM) is a programmed, transcription-coupled diversification mechanism operating within proliferating germinal center B lymphocytes (centroblasts) that introduces point mutations into the rearranged variable (V(D)J) exons of immunoglobulin heavy (IGH) and light (IGK, IGL) chain loci at a rate of 10⁻³ substitutions per base pair per cell division—approximately 10⁶-fold higher than the spontaneous background mutation rate of human somatic dna-replication (~10⁻⁹ to 10⁻¹⁰ per base pair per division). Discovered at the molecular level through the identification of Activation-Induced Cytidine Deaminase (AID, encoded by AICDA) by Tasuku Honjo and colleagues (Muramatsu et al., 2000), somatic hypermutation reshapes the antigen-binding complementarity-determining regions (CDRs) of antibodies. B-cell clones whose mutated B-cell receptors bind foreign antigens on follicular dendritic cells with higher affinity outcompete lower-affinity clones for T follicular helper (T_FH) cell survival signals, driving affinity maturation of the humoral immune response by 100- to 10,000-fold.

Biochemically, AID belongs to the zinc-dependent AID/APOBEC polynucleotide cytidine deaminase superfamily, which catalyzes the hydrolytic deamination of deoxycytidine (dC) to deoxyuridine (dU) exclusively on single-stranded DNA (ssDNA). Rather than repairing the resulting promutagenic U:G mismatch with high fidelity, germinal center B cells hijack two canonical dna-repair pathways—Uracil-DNA Glycosylase (UNG)-mediated base-excision-repair and MutSα (MSH2/MSH6)-mediated mismatch-repair—by recruiting error-prone translesion DNA polymerases such as DNA Polymerase η (Pol η) and REV1. When AID or its antiviral sister enzymes APOBEC3A and APOBEC3B act off-target outside immunoglobulin loci, they generate clustered strand-coordinated hypermutation storms (kataegis) and represent one of the most prevalent endogenous mutational signatures (COSMIC SBS2 and SBS13) across human breast, bladder, cervical, lung, and lymphoid cancers.

Zn2+-Dependent Cytidine Deamination on Single-Stranded DNA

The catalytic active site of AID (a 24 kDa monomer encoded on human chromosome 12p13) coordinates a single catalytic Zn²⁺ ion via a conserved histidine and two cysteines (H56, C87, C90) alongside a catalytic glutamate (E58) that acts as a general proton shuttle. When single-stranded DNA is exposed inside a transcription bubble or on the displaced non-template strand of a nascent R-loop within the first 1.5 to 2.0 kb downstream of the immunoglobulin variable-region promoter, AID flips a target deoxycytidine base into its catalytic pocket. The Zn²⁺-activated hydroxide ion attacks the C4 carbon of the pyrimidine ring, releasing ammonia (NH₃) and converting the C4 amino group into a keto oxygen to yield deoxyuridine (dU) paired opposite template guanine (a U:G mismatch):

dC + H₂O → dU + NH₃

Because AID cannot deaminate double-stranded B-DNA, its activity requires active transcription by RNA Polymerase II stalled by the elongation factor SPT5 and the RNA exosome complex, which degrades the nascent RNA transcript to expose both the non-template and template DNA strands as transient single-stranded substrates.

WRCY / RGYW Hotspots vs. SYC Coldspots

Structural crystallography of AID and its family members reveals that a surface-exposed substrate-recognition loop (Loop 7, residues 113–123) dictates local sequence specificity around the target cytosine. AID preferentially deaminates cytosines embedded within the four-nucleotide WRCY hotspot motif (where W = A or T, R = purine A or G, C = target cytosine, and Y = pyrimidine C or T; paired on the opposite strand to the reverse-complement RGYW motif), such as 5′-AGCT-3′ or 5′-AAC(T/C)-3′. Over evolutionary time, vertebrate immunoglobulin variable segments have evolved a high density of AGCT and WRCY codons inside their hypervariable Complementarity-Determining Regions (CDR1, CDR2, CDR3) while enriching SYC coldspot motifs (where S = G or C, Y = C or T) inside the structural Framework Regions (FR1–FR4), focusing mutational diversification onto the antigen-contact loops while preserving the immunoglobulin β-barrel fold.

If a U:G mismatch generated by AID were processed by canonical high-fidelity repair, Uracil-DNA Glycosylase (UNG) and DNA Polymerase β would restore the original C:G base pair without mutation. Instead, as established by Michael Neuberger's two-phase model of somatic hypermutation (Di Noia and Neuberger, 2007), germinal center B cells process the U:G lesion through three mutagenic pathways that generate a balanced spectrum of transitions and transversions at both C:G and A:T base pairs:

1. Direct Replication Across Uracil (C:G Transitions): If the replication fork arrives at the U:G lesion before repair enzymes excise the uracil, the replicative DNA polymerase reads deoxyuridine as thymidine and incorporates deoxyadenosine (dA) opposite dU. In the next replication cycle, this yields a C:G → T:A transition mutation.
2. Phase 1B — Error-Prone Base Excision Repair via UNG and REV1 (C:G Transitions and Transversions): Uracil-DNA Glycosylase (UNG) excises the uracil base by cleaving the N-glycosidic bond, leaving an abasic (AP) site opposite guanine. Rather than completing high-fidelity repair, the translesion deoxycytidyl transferase REV1 and error-prone polymerases (Pol ζ, Pol η) bypass the non-instructional AP site by inserting any of the four dNTPs (dA, dC, dG, or dT), generating both C:G → T:A transitions and C:G → G:C / C:G → A:T transversions. If APE1 (Apurinic/apyrimidinic endonuclease 1) cleaves the phosphodiester backbone at clustered AP sites on opposite strands within immunoglobulin switch (S) regions, the resulting staggered double-strand breaks drive Class-Switch Recombination (CSR).
3. Phase 2 — Error-Prone Mismatch Repair via MutSα and Pol η (A:T Mutations): The heterodimeric mismatch recognition complex MutSα (MSH2/MSH6) recognizes the U:G mismatch and recruits Exonuclease 1 (EXO1) to excise a single-stranded gap of 20 to 100 nucleotides encompassing surrounding A:T base pairs. Monoubiquitinated PCNA (at lysine K164) then recruits the low-fidelity Y-family translesion polymerase DNA Polymerase η (Pol η, POLH) to resynthesize the gap. Pol η exhibits a high misincorporation rate (~3 × 10⁻²) specifically when copying template thymidines within WA / TW motifs (5′-AA-3′ or 5′-TA-3′), introducing transitions and transversions at A:T base pairs.

Whereas AID prefers 5′-WRCY-3′ motifs in B cells, its innate antiviral paralogs APOBEC3A (A3A) and APOBEC3B (A3B) (encoded within the seven-gene APOBEC3A–APOBEC3H cluster on human chromosome 22q13) recognize a 5′-TCN-3′ sequence context (specifically 5′-YTCA-3′ hairpin loops for A3A and 5′-RTCA-3′ for A3B). Under physiological conditions, APOBEC3 enzymes restrict retroviruses (such as HIV-1 lacking Vif), endogenous retrotransposons, and DNA viruses (HPV, HBV) by hypermutating single-stranded viral replication intermediates.

In human tumors, aberrant overexpression or episodic bursts of APOBEC3A and APOBEC3B deaminate single-stranded genomic DNA exposed on lagging-strand replication templates, stalled replication forks, or resected 3′ overhangs at double-strand break repair intermediates. As cataloged by Serena Nik-Zainal et al. (2012) and Ludmil Alexandrov et al. (2013), APOBEC processing via replication and UNG/REV1 generates two coupled single-base substitution signatures across >50% of human cancer types: COSMIC SBS2 (TCN → TTN transitions) and COSMIC SBS13 (TCN → TGN and TCN → TAN transversions via REV1). When processive APOBEC3 enzymes act along a continuous kilobase tract of resected single-stranded DNA at a chromosome break or chromothripsis junction, they produce kataegis—localized clusters of dozens of strand-coordinated C → T and C → G mutations spaced 10 to 1,000 bp apart on the same parental strand. Meanwhile, in germinal-center-derived B-cell lymphomas (such as diffuse large B-cell lymphoma and Burkitt lymphoma), off-target AID activity at super-enhancer R-loops drives chromosomal translocations (such as IGH–MYC t(8;14) and IGH–BCL2 t(14;18)).

How can an enzyme that only deaminates cytosine (AID) generate half of all mutations at A:T base pairs?

AID itself never modifies adenine or thymine directly; it only converts deoxycytidine to deoxyuridine (C → U). However, when the mismatch repair complex MutSα (MSH2/MSH6) recognizes the resulting U:G mismatch during Phase 2 of somatic hypermutation, Exonuclease 1 excises a 20–100 nucleotide single-stranded patch around the uracil, and monoubiquitinated PCNA recruits error-prone DNA Polymerase η (Pol η) to fill the gap. Pol η frequently misincorporates nucleotides opposite template thymidines at WA/TW motifs, creating the A:T mutations.

Why does UNG deficiency shift somatic hypermutation at C:G pairs almost entirely to C:G → T:A transitions?

Without Uracil-DNA Glycosylase (UNG), the uracil base generated by AID cannot be excised to form a non-instructional abasic (AP) site. Consequently, when the replication fork passes over the intact deoxyuridine, replicative DNA polymerases pair dU with deoxyadenosine (dA) just as they would pair thymidine, converting nearly 100% of C:G lesions into C:G → T:A transitions and eliminating the AP-site bypass transversions mediated by REV1.

How are AID-induced mutations (SBS84/SBS9) distinguished from APOBEC3-induced mutations (SBS2/SBS13) in cancer genomes?

The two deaminase classes are distinguished by their local trinucleotide sequence context and genomic distribution. AID targets purine-preceded cytosines in the WRCY motif (5′-[A/T][A/G]C[C/T]-3′) and focuses within the first 2 kb of transcribed B-cell genes and super-enhancers (producing COSMIC signatures SBS84 and SBS85, plus Pol η-linked SBS9). Conversely, APOBEC3A and APOBEC3B target thymine-preceded cytosines in the TCN motif (5′-TC[A/T]-3′), generating genome-wide SBS2 (C → T) and SBS13 (C → G/A) mutations and strand-coordinated kataegis clusters.

1. Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., & Honjo, T. (2000). "Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme." Cell, 102(5), 553–563. https://doi.org/10.1016/S0092-8674(00)00078-700078-7)
2. Di Noia, J. M., & Neuberger, M. S. (2007). "Molecular mechanisms of antibody somatic hypermutation." Annual Review of Biochemistry, 76, 1–22. https://doi.org/10.1146/annurev.biochem.76.061705.090740
3. Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., Menzies, A., Martin, S., Leung, K., Chen, L., Leroy, C., Ramakrishna, M., Rance, R., Lau, K. W., Mudie, L. J., Varela, I., McBride, D. J., Bignell, G. R., Steel, M., Andrew, F., Davies, H., Tarpey, P. S., Butler, A. P., Teague, J. W., Latimer, C., & Stratton, M. R. (2012). "Mutational processes molding the genomes of 21 breast cancers." Cell, 149(5), 979–993. https://doi.org/10.1016/j.cell.2012.04.024
4. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A.-L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jäger, N., Jones, D. T. W., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., López-Otín, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N. J., Valdés-Mas, R., van Buuren, M. M., van 't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., & Stratton, M. R. (2013). "Signatures of mutational processes in human cancer." Nature, 500(7463), 415–421. https://doi.org/10.1038/nature12477